MoleculeDx is a premier cancer diagnostics startup, a University of Pittsburgh spin-off in Pittsburgh, PA, in operation since 2024. Our mission is to provide transformative and state-of-the-art cancer screening and prognosticator technologies to manage human cancers. Our goal is to screen cancers that are still in their infancy so that the patients can be treated effectively. For early liver cancer, surgical treatment produces long term survival for 90% of the patients, while for late-stage liver cancer, less than 20% of the patients survive 2 years. Sensitive screening of early liver cancer matters. Our company provides a serum fusion transcript-based machine-learning technology to make effective screening for early-stage liver cancers and to make liver cancer curable.

MoleculeDx Inc

Org chart

Teams

Offices

MoleculeDx Inc

Org chart

Teams

Offices

Related companies